Changeflow GovPing Pharma & Drug Safety Multispecific Heavy Chain Antibodies with Modif...
Routine Notice Added Final

Multispecific Heavy Chain Antibodies with Modified Constant Regions

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4186564A1, filed by Teneoone, Inc., covering multispecific heavy chain antibodies (nanobodies) with modified constant regions. The invention relates to Fc region modifications affecting effector functions. The application designates all EPC contracting states including DE, FR, GB, IT, NL, ES, BE, CH, and others.

What changed

The EPO published patent application EP4186564A1 on March 25, 2026, covering multispecific heavy chain antibodies with modified constant regions. The invention by Teneoone, Inc. involves camelid-derived heavy chain-only antibodies (VHHs) with engineered Fc regions. IPC classifications indicate therapeutic applications including oncology (A61P 35/00, A61P 35/02) and CD38-targeting constructs (C07K 16/28). The application designates 33 EPC contracting states across Europe.

This is a patent publication notice conveying intellectual property rights. No compliance actions are required from regulated entities. Companies developing multispecific antibody therapeutics or biosimilar constructs should review the patent claims to assess potential freedom-to-operate implications or licensing considerations.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS

Publication EP4186564A1 Kind: A1 Mar 25, 2026

Applicants

Teneoone, Inc.

Inventors

HARRIS, Katherine, SCHELLENBERGER, Ute, VAFA, Omid, TRINKLEIN, Nathan, VAN SCHOOTEN, Wim, FORCE ALDRED, Shelley, PHAM, Duy, CLARKE, Starlynn

IPC Classifications

A61P 35/00 20060101AFI20230421BHEP A61P 35/02 20060101ALI20230421BHEP C07K 16/28 20060101ALI20230421BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for ChangeBridge: EPO Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
March 25th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4186564A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254.1 Biotechnology 3254 Pharmaceutical Manufacturing
Activity scope
Biotechnology Patent Filing Therapeutic Antibody Development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.